Clinical and urodynamic benefit of adding antimuscarinics after a loss of efficacy of intradetrusor botulinum toxin in patients with multiple sclerosis.

Adrien Haegel, Camille Chesnel, Maëlys Teng, Magdaline Vivier, Camille Noël, Gérard Amarenco, Claire Hentzen

Erratum issuedAbstract read

In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Phenotyping Overactive Bladder - Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI-RS 2025.Neurourology and urodynamics · 2026
Review

4 · The record

Corrections and comments

Erratum issued
Correction: Clinical and urodynamic benefit of adding antimuscarinics after a loss of efficacy of intradetrusor botulinum toxin in patients with multiple sclerosis.2025

5 · Who and what money

Authors and funding

7 authors.

Adrien HaegelGREEN Group of clinical REsEarch in Neurourology, Sorbonne University, AP-HP, Hôpital Pitié Salpêtrière, GRC 01, Paris, F-75013, France. adrien.haegel@aphp.fr.ORCID https://orcid.org/0009-0000-9917-5799

Camille ChesnelGREEN Group of clinical REsEarch in Neurourology, Sorbonne University, AP-HP, Hôpital Pitié Salpêtrière, GRC 01, Paris, F-75013, France.

Maëlys TengGREEN Group of clinical REsEarch in Neurourology, Sorbonne University, AP-HP, Hôpital Pitié Salpêtrière, GRC 01, Paris, F-75013, France.

Magdaline VivierGREEN Group of clinical REsEarch in Neurourology, Sorbonne University, AP-HP, Hôpital Pitié Salpêtrière, GRC 01, Paris, F-75013, France.

Camille NoëlGREEN Group of clinical REsEarch in Neurourology, Sorbonne University, AP-HP, Hôpital Pitié Salpêtrière, GRC 01, Paris, F-75013, France.

Gérard AmarencoGREEN Group of clinical REsEarch in Neurourology, Sorbonne University, AP-HP, Hôpital Pitié Salpêtrière, GRC 01, Paris, F-75013, France.

Claire HentzenGREEN Group of clinical REsEarch in Neurourology, Sorbonne University, AP-HP, Hôpital Pitié Salpêtrière, GRC 01, Paris, F-75013, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim was to assess in real-life practice the effectiveness of adding antimuscarinics drug (AM) when facing a loss of efficacy of intradetrusor botulinum toxin A (IDBTX-A) in patients with multiple sclerosis (PwMS) on overactive bladder symptoms and urodynamic parameters.

methodsAll PwMS who had IDBTX-A injections between January 2023 and December 2023 were screened. Patients with a loss of efficacy of IDBTX-A on bladder symptoms and/or detrusor overactivity, and who received AM as an add-on therapy were included. Data collected were urodynamic parameters (bladder capacity, filling volume of first detrusor overactivity (DO), maximal detrusor pressure at DO, area under curve of detrusor pressure (AUUC)), and clinical parameters (persistence of spontaneous voiding, number of self-catheterization, nocturia, persistence of urgency and/or urge incontinence, number of urinary tract infections (UTI)).

resultsThirty-four patients were included (mean age 49 ± 8.7; 20 (58%) women). The rate of patients with DO significantly decreased after AM addition (27 (81%) before AM addition vs. 11 (33%) patients after; p < 0.01). Bladder capacity increase from 311 ± 124 ml to 381 ± 70 ml (p < 0.01) was the only other significant change in urodynamics after AM. The only clinical change was a decrease in the number of patients reporting urgency from 23 (67%) to 11 (32%) (p < 0.01).

conclusionAdding antimuscarinics to intradetrusor botulinum toxin for treating DO in PwMS reduces the rate of patients with DO, improves bladder capacity and the occurrence of urgencies.

Indexed as

Botulinum Toxins, Type AMultiple SclerosisMuscarinic AntagonistsNeuromuscular AgentsUrinary Bladder, OveractiveAdministration, IntravesicalAdultDrug Therapy, CombinationFemaleHumansInjections, IntramuscularMaleMiddle AgedRetrospective StudiesTreatment OutcomeUrodynamicsBotulinum Toxins, Type AMuscarinic AntagonistsNeuromuscular AgentsBotulinum toxinsMultiple sclerosisMuscarinic antagonistsUrinary bladder, neurogenicUrinary bladder, overactive

Identifiers

PMID40327133

DOI10.1007/s00345-025-05655-9

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.